Statements

Therapeutic response

Precision oncology relationships for therapeutic response.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Crizotinib
Sensitivity (Supports)	v::ALK	Anaplastic Large Cell Lymphoma	Crizotinib
Sensitivity (Supports)	v::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
Sensitivity (Supports)	PD-L1 >= 1%	Bladder Urothelial Carcinoma	Nivolumab
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Esophageal Adenocarcinoma	Fluorouracil, Nivolumab, Oxaliplatin
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Esophageal Adenocarcinoma	Nivolumab, Oxaliplatin
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Esophagogastric Adenocarcinoma	Fluorouracil, Nivolumab, Oxaliplatin
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Esophagogastric Adenocarcinoma	Nivolumab, Oxaliplatin
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Nivolumab, Oxaliplatin
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 5	Adenocarcinoma of the Gastroesophageal Junction	Nivolumab, Oxaliplatin
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Docetaxel, Nivolumab
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
Sensitivity (Supports)	PDGFRA p.D842V	Gastrointestinal Stromal Tumor	Avapritinib
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab
Sensitivity (Supports)	FOLR1 positive	Ovarian Epithelial Tumor	Mirvetuximab soravtansine
Sensitivity (Supports)	FOLR1 positive	High-Grade Serous Fallopian Tube Cancer	Mirvetuximab soravtansine
Sensitivity (Supports)	FOLR1 positive	Peritoneal Serous Carcinoma	Mirvetuximab soravtansine
Sensitivity (Supports)	BCR::ABL1, CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin
Sensitivity (Supports)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Carboplatin, Etoposide, Ifosfamide, Rituximab
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib
Sensitivity (Supports)	EGFR somatic variants	Non-Small Cell Lung Cancer	Afatinib
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib
Sensitivity (Supports)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (Supports)	TSC1 oncogenic variants	Renal Angiomyolipoma	Everolimus
Sensitivity (Supports)	TSC2 oncogenic variants	Renal Angiomyolipoma	Everolimus
Sensitivity (Supports)	TSC1 oncogenic variants	Anaplastic Thyroid Cancer	Everolimus
Sensitivity (Supports)	TSC2 oncogenic variants	Anaplastic Thyroid Cancer	Everolimus
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vinorelbine
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
Sensitivity (Supports)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vinorelbine
Sensitivity (Supports)	PDGFRA p.D842V	Gastrointestinal Stromal Tumor	Avapritinib
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Gemcitabine, Oxaliplatin, Rituximab
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Gemcitabine, Oxaliplatin, Rituximab
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Sensitivity (Supports)	CD30 +	Anaplastic Large Cell Lymphoma	Brentuximab vedotin
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
Sensitivity (Supports)	HER2-positive	Intraductal Papillary Neoplasm of the Bile Duct	Zanidatamab
Sensitivity (Supports)	HER2-positive	Intracholecystic Papillary Neoplasm	Zanidatamab
Sensitivity (Supports)	HER2-positive	Cholangiocarcinoma	Zanidatamab
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Taletrectinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Dacomitinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Dacomitinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (Supports)	c-Met >= 50%	Lung Non-Squamous Non-Small Cell Carcinoma	Telisotuzumab Vedotin
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
Sensitivity (Supports)	CD22 +	Chronic Myeloid Leukemia, BCR-ABL1+	Bosutinib
Sensitivity (Supports)	CD22 +	Chronic Myeloid Leukemia, BCR-ABL1+	Bosutinib
Sensitivity (Supports)	CD22 +	Chronic Myeloid Leukemia, BCR-ABL1+	Bosutinib
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Bendamustine, Brentuximab vedotin
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib
Sensitivity (Supports)	KRAS p.G12C	Colorectal Adenocarcinoma	Adagrasib, Cetuximab
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib
Sensitivity (Supports)	KRAS p.G12C	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib
Sensitivity (Supports)	KRAS p.G12V	Low-Grade Serous Ovarian Cancer	Avutometinib, Defactinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Chlorambucil, Mitoxantrone, Prednisolone, Rituximab
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Interferon Alpha, Prednisolone, Rituximab
Sensitivity (Supports)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (Supports)	Wild type HRAS, Wild type KRAS	Colorectal Adenocarcinoma	Panitumumab
Sensitivity (Supports)	H3-3A p.K27M	Diffuse Midline Glioma	Dordaviprone
Sensitivity (Supports)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Vemurafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Vemurafenib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	AKT1 somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	AKT1 somatic variants, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	AKT1 somatic variants, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	AKT1 amplification, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PR positive, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, ESR1 oncogenic variants, HER2-negative	Invasive Breast Carcinoma	Imlunestrant
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
Sensitivity (Supports)	dMMR	Any solid tumor	Pembrolizumab
Sensitivity (Supports)	MSI-H	Any solid tumor	Pembrolizumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
Sensitivity (Supports)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Cisplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Squamous Cell Carcinoma	Pembrolizumab
Sensitivity (Supports)	MSI-L	Endometrial Carcinoma	Lenvatinib, Pembrolizumab
Sensitivity (Supports)	pMMR	Endometrial Carcinoma	Pembrolizumab
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Pembrolizumab
Sensitivity (Supports)	TMB-H (>= 10 mutations / Mb)	Any solid tumor	Pembrolizumab
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Ovarian Epithelial Tumor	Bevacizumab, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Peritoneal Serous Carcinoma	Bevacizumab, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (Supports)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (Supports)	17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide
Sensitivity (Supports)	t(15;17)	APL with PML-RARA	Arsenic trioxide
Sensitivity (Supports)	t(15;17)	APL with PML-RARA	Arsenic trioxide
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Rituximab
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (Supports)	IDH1 p.R132C	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132G	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132H	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132L	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132S	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172K	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172M	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172G	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172S	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172W	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132C	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132G	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132H	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132L	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132S	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172K	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172M	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172G	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172S	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172W	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
Sensitivity (Supports)	PD-L1 < 1%	Melanoma	Nivolumab, Relatlimab
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	v::RET	Medullary Thyroid Cancer	Vandetanib
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 50%	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 10% TIIC	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel
Sensitivity (Supports)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Atezolizumab, Cobimetinib, Vemurafenib
Sensitivity (Supports)	ER positive, ESR1 oncogenic variants, HER2-negative	Invasive Breast Carcinoma	Elacestrant
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Rituximab
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib
Sensitivity (Supports)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib
Sensitivity (Supports)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib
Sensitivity (Supports)	PDGFRA rearrangements	Myeloproliferative Neoplasm	Imatinib
Sensitivity (Supports)	PDGFRB rearrangements	Myeloproliferative Neoplasm	Imatinib
Sensitivity (Supports)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Elacestrant
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Elacestrant
Sensitivity (Supports)	EGFR somatic variants	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Invasive Breast Carcinoma	Datopotamab deruxtecan
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Datopotamab deruxtecan
Sensitivity (Supports)	HER2-negative, PR positive	Non-Small Cell Lung Cancer	Datopotamab deruxtecan
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Datopotamab deruxtecan
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Dostarlimab
Sensitivity (Supports)	dMMR	Any solid tumor	Dostarlimab
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisone
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Rituximab
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pemetrexed, Tislelizumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pemetrexed, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 5%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib
Sensitivity (Supports)	ER positive, HER2-positive, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Capecitabine, Lapatinib
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	FGFR2::v	Intrahepatic Cholangiocarcinoma	Futibatinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Asciminib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
Sensitivity (Supports)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3::BAIAP2L1	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Gefitinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Gefitinib
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	ERBB2 amplification	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan
Sensitivity (Supports)	ERBB2 oncogenic variants	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan
Sensitivity (Supports)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan
Sensitivity (Supports)	ERBB2 amplification	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan
Sensitivity (Supports)	ER positive, HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	HER2-low, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	ER positive, HER2-low, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	ER positive, HER2-ultralow	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	HER2-ultralow, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	ER positive, HER2-ultralow, PR positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Gilteritinib
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Gilteritinib
Sensitivity (Supports)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin
Sensitivity (Supports)	BCR::ABL1, CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA amplification	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	AKT1 amplification, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	AKT1 somatic variants, ER positive, HER2-negative	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PTEN nonsense variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PTEN frameshift variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PTEN splice site variants	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PTEN deletion	Invasive Breast Carcinoma	Capivasertib, Fulvestrant
Sensitivity (Supports)	CD33 +	Acute Lymphoid Leukemia	Gemtuzumab ozogamicin
Sensitivity (Supports)	CD33 +	Acute Lymphoid Leukemia	Gemtuzumab ozogamicin
Sensitivity (Supports)	CD20 +	Follicular Lymphoma	Rituximab
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
Sensitivity (Supports)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Oxaliplatin, Panitumumab
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Fluorouracil, Irinotecan, Panitumumab
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Cisplatin, Cytarabine, Etoposide
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Sunvozertinib
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib
Sensitivity (Supports)	FLT3-ITD	Acute Lymphoid Leukemia	Gilteritinib
Sensitivity (Supports)	FLT3 p.D835Y	Acute Lymphoid Leukemia	Gilteritinib
Sensitivity (Supports)	FLT3 p.D835A	Acute Lymphoid Leukemia	Gilteritinib
Sensitivity (Supports)	FLT3 p.D835E	Acute Lymphoid Leukemia	Gilteritinib
Sensitivity (Supports)	FLT3 p.D835H	Acute Lymphoid Leukemia	Gilteritinib
Sensitivity (Supports)	FLT3 p.D835N	Acute Lymphoid Leukemia	Gilteritinib
Sensitivity (Supports)	FLT3 p.D835S	Acute Lymphoid Leukemia	Gilteritinib
Sensitivity (Supports)	FLT3 p.D835V	Acute Lymphoid Leukemia	Gilteritinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
Sensitivity (Supports)	ER positive, ESR1 oncogenic variants, HER2-negative	Invasive Breast Carcinoma	Elacestrant
Sensitivity (Supports)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Zongertinib
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib
Sensitivity (Supports)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab
Sensitivity (Supports)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
Sensitivity (Supports)	EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Oxaliplatin
Sensitivity (Supports)	IDH2 p.R140Q	Acute Myeloid Leukemia	Enasidenib
Sensitivity (Supports)	IDH2 p.R140L	Acute Myeloid Leukemia	Enasidenib
Sensitivity (Supports)	IDH2 p.R140G	Acute Myeloid Leukemia	Enasidenib
Sensitivity (Supports)	IDH2 p.R140W	Acute Myeloid Leukemia	Enasidenib
Sensitivity (Supports)	IDH2 p.R172K	Acute Myeloid Leukemia	Enasidenib
Sensitivity (Supports)	IDH2 p.R172M	Acute Myeloid Leukemia	Enasidenib
Sensitivity (Supports)	IDH2 p.R172G	Acute Myeloid Leukemia	Enasidenib
Sensitivity (Supports)	IDH2 p.R172S	Acute Myeloid Leukemia	Enasidenib
Sensitivity (Supports)	IDH2 p.R172W	Acute Myeloid Leukemia	Enasidenib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	PD-L1 >= 1%	Bladder Urothelial Carcinoma	Nivolumab
Sensitivity (Supports)	CD33 +	Acute Lymphoid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
Sensitivity (Supports)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (Supports)	17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (Supports)	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (Supports)	17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin, Dacarbazine, Doxorubicin, Vinblastine
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin
Sensitivity (Supports)	CD30 +	Cutaneous T-cell Lymphoma	Brentuximab vedotin
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Paclitaxel
Sensitivity (Supports)	pMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Olaparib, Paclitaxel
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed
Sensitivity (Supports)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3::BAIAP2L1	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Capmatinib
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Capmatinib
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Adagrasib
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Palbociclib
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (Supports)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (Supports)	17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Durvalumab
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	FOLR1 positive	Ovarian Epithelial Tumor	Mirvetuximab soravtansine
Sensitivity (Supports)	FOLR1 positive	High-Grade Serous Fallopian Tube Cancer	Mirvetuximab soravtansine
Sensitivity (Supports)	FOLR1 positive	Peritoneal Serous Carcinoma	Mirvetuximab soravtansine
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Cemiplimab
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR	Non-Small Cell Lung Cancer	Cemiplimab
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib
Sensitivity (Supports)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Imatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Imatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Imatinib
Sensitivity (Supports)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib
Sensitivity (Supports)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib
Sensitivity (Supports)	KIT p.D816V	Aggressive Systemic Mastocytosis	Imatinib
Sensitivity (Supports)	FIP1L1::PDGFRA	Chronic Eosinophilic Leukemia, NOS	Imatinib
Sensitivity (Supports)	CD117 +	Gastrointestinal Stromal Tumor	Imatinib
Sensitivity (Supports)	FIP1L1::PDGFRA	Gastrointestinal Stromal Tumor	Imatinib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Everolimus, Exemestane
Sensitivity (Supports)	v::RET	Medullary Thyroid Cancer	Vandetanib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide
Sensitivity (Supports)	PML::RARA	APL with PML-RARA	Arsenic trioxide
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Carboplatin, Dostarlimab, Paclitaxel
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Dostarlimab
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Dostarlimab
Sensitivity (Supports)	BRAF rearrangements	Low-Grade Glioma, NOS	Tovorafenib
Sensitivity (Supports)	v::BRAF	Low-Grade Glioma, NOS	Tovorafenib
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Tovorafenib
Sensitivity (Supports)	BRAF p.V600K	Low-Grade Glioma, NOS	Tovorafenib
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
Sensitivity (Supports)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Alpelisib, Fulvestrant
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Pralsetinib
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Elacestrant
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Elacestrant
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Zolbetuximab
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Zolbetuximab
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab, Irinotecan
Sensitivity (Supports)	EGFR positive, Wild type KRAS	Colorectal Adenocarcinoma	Cetuximab
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
Sensitivity (Supports)	BRAF p.V600E	Colorectal Adenocarcinoma	Cetuximab, Encorafenib, Fluorouracil, Irinotecan
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Gefitinib
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Carboplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	pMMR	Endometrial Carcinoma	Durvalumab, Olaparib
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Selpercatinib
Sensitivity (Supports)	v::RET	Papillary Thyroid Cancer	Selpercatinib
Sensitivity (Supports)	RET p.M918T	Medullary Thyroid Cancer	Selpercatinib
Sensitivity (Supports)	v::RET	Any solid tumor	Selpercatinib
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Afatinib
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (Supports)	CD274 amplification, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Pembrolizumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Pembrolizumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Carboplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	PD-L1 >= 50%	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	MSI-H	Endometrial Carcinoma	Pembrolizumab
Sensitivity (Supports)	dMMR	Endometrial Carcinoma	Pembrolizumab
Sensitivity (Supports)	MSI-H	Esophagogastric Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	dMMR	Esophagogastric Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	MSI-H	Gastrointestinal Stromal Tumor	Pembrolizumab
Sensitivity (Supports)	dMMR	Gastrointestinal Stromal Tumor	Pembrolizumab
Sensitivity (Supports)	MSI-H	Cholangiocarcinoma	Pembrolizumab
Sensitivity (Supports)	dMMR	Cholangiocarcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Carboplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Pembrolizumab
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Paclitaxel, Pembrolizumab
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Nab-paclitaxel, Pembrolizumab
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
Sensitivity (Supports)	HER2-positive, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Carboplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	17p deletion	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
Sensitivity (Supports)	HER2-positive	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
Sensitivity (Supports)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Pemigatinib
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Pemigatinib
Sensitivity (Supports)	FGFR1 rearrangements	Myeloid/Lymphoid Neoplasms	Pemigatinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Entrectinib
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Entrectinib
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Entrectinib
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Amivantamab
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Lazertinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Amivantamab, Carboplatin, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Afatinib
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Repotrectinib
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Repotrectinib
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Repotrectinib
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Repotrectinib
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	5q deletion	Myeloproliferative Neoplasm	Lenalidomide
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Crizotinib
Sensitivity (Supports)	v::ALK	Anaplastic Large Cell Lymphoma	Crizotinib
Sensitivity (Supports)	v::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel
Sensitivity (Supports)	IDH1 p.R132C	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132G	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132H	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132L	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132S	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172K	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172M	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172G	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172S	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172W	Astrocytoma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132C	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132G	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132H	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132L	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH1 p.R132S	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172K	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172M	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172G	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172S	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	IDH2 p.R172W	Oligodendroglioma	Vorasidenib
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Infigratinib
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Entrectinib
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Entrectinib
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Entrectinib
Sensitivity (Supports)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (Supports)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Dacomitinib
Sensitivity (Supports)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	CD22 +	Acute Lymphoid Leukemia	Inotuzumab ozogamicin
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
Sensitivity (Supports)	BCR::ABL1, CD19 +	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib
Sensitivity (Supports)	CD30 +	Cutaneous T-cell Lymphoma	Brentuximab vedotin
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin
Sensitivity (Supports)	CD30 +	Hodgkin Lymphoma	Brentuximab vedotin
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Asciminib
Sensitivity (Supports)	EGFR Exon 20 (Insertion)	Non-Small Cell Lung Cancer	Mobocertinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Neratinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Cobimetinib, Vemurafenib
Sensitivity (Supports)	CD30 +, HER2-negative	Hodgkin Lymphoma	Brentuximab vedotin, Carboplatin, Etoposide, Ifosfamide
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Azacitidine, Ivosidenib
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132C	Myelodysplastic Syndromes	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132G	Myelodysplastic Syndromes	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132H	Myelodysplastic Syndromes	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132L	Myelodysplastic Syndromes	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132S	Myelodysplastic Syndromes	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Dasatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Dasatinib
Sensitivity (Supports)	ER negative	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (Supports)	ER negative	Invasive Breast Carcinoma	Fulvestrant
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Esophageal Adenocarcinoma	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Pembrolizumab
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Nilotinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	ATM pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	ATM oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	ATR oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	ATR pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	FANCA oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	FANCA pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	MLH1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	MLH1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	MRE11 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	MRE11 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	NBN oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	NBN pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (Supports)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Dacomitinib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Niraparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Niraparib
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Capmatinib
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Capmatinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Entrectinib
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Entrectinib
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Entrectinib
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Entrectinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Pembrolizumab
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Sacituzumab govitecan
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Blinatumomab
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Exemestane
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Nivolumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Nivolumab
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Gemcitabine
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Selpercatinib
Sensitivity (Supports)	RET oncogenic variants	Medullary Thyroid Cancer	Selpercatinib
Sensitivity (Supports)	v::RET	Anaplastic Thyroid Cancer	Selpercatinib
Sensitivity (Supports)	v::RET	Any solid tumor	Selpercatinib
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Quizartinib
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Quizartinib
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Idarubicin, Quizartinib
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Cytarabine, Methotrexate, Ponatinib, Prednisone, Vincristine
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
Sensitivity (Supports)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Exemestane
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Tamoxifen
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Letrozole
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Abemaciclib, Anastrozole
Sensitivity (Supports)	ABL1 p.T315I	Chronic Myelogenous Leukemia	Ponatinib
Sensitivity (Supports)	BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
Sensitivity (Supports)	ABL1 p.T315I, BCR::ABL1	Acute Lymphoid Leukemia	Ponatinib
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	ATM pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	ATM oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BARD1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BARD1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRIP1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRIP1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	CHEK1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	CHEK1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	FANCL pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	FANCL oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	RAD51B pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	RAD51B oncogenic variants	Prostate Adenocarcinoma	Talazoparib
Sensitivity (Supports)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	RAD51D pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	RAD51D oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	RAD54L pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	RAD54L oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab
Sensitivity (Supports)	KRAS p.G12C	Non-Small Cell Lung Cancer	Sotorasib
Sensitivity (Supports)	v::RET	Non-Small Cell Lung Cancer	Pralsetinib
Sensitivity (Supports)	v::RET	Papillary Thyroid Cancer	Pralsetinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab, Vinorelbine
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Erlotinib, Ramucirumab
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Niraparib, Prednisolone
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Nivolumab
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
Sensitivity (Supports)	FGFR2::v	Cholangiocarcinoma	Futibatinib
Sensitivity (Supports)	FGFR2 rearrangements	Cholangiocarcinoma	Futibatinib
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	v::ROS1	Non-Small Cell Lung Cancer	Repotrectinib
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Repotrectinib
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Repotrectinib
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Repotrectinib
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
Sensitivity (Supports)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
Sensitivity (Supports)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
Sensitivity (Supports)	HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
Sensitivity (Supports)	ER positive, HER2-negative, PIK3CA somatic variants, PR positive	Invasive Breast Carcinoma	Fulvestrant, Inavolisib, Palbociclib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Trametinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Anaplastic Thyroid Cancer	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Any solid tumor	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Low-Grade Glioma, NOS	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Panitumumab
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Vemurafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Vemurafenib
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Burkitt Lymphoma	Corticosteroid, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Methotrexate, Rituximab, Vincristine
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole
Sensitivity (Supports)	Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Cetuximab, Fluorouracil, Irinotecan
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Ziftomenib
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Nivolumab
Sensitivity (Supports)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (Supports)	17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (Supports)	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax
Sensitivity (Supports)	ER negative, HER2-negative, PR negative	Invasive Breast Carcinoma	Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Zolbetuximab
Sensitivity (Supports)	CLDN18.2 >= 75%, HER2-negative	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Zolbetuximab
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Fulvestrant, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Anastrozole, Goserelin, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
Sensitivity (Supports)	HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
Sensitivity (Supports)	ER positive, HER2-negative, PR positive	Invasive Breast Carcinoma	Goserelin, Letrozole, Ribociclib
Sensitivity (Supports)	PD-L1 >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Nivolumab, Oxaliplatin
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Erlotinib
Sensitivity (Supports)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Sevabertinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	HER2-positive	Intraductal Papillary Neoplasm of the Bile Duct	Zanidatamab
Sensitivity (Supports)	HER2-positive	Intracholecystic Papillary Neoplasm	Zanidatamab
Sensitivity (Supports)	HER2-positive	Cholangiocarcinoma	Zanidatamab
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Trametinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (Supports)	BRAF p.V600K	Non-Small Cell Lung Cancer	Dabrafenib, Trametinib
Sensitivity (Supports)	v::NTRK1	Any solid tumor	Larotrectinib
Sensitivity (Supports)	v::NTRK2	Any solid tumor	Larotrectinib
Sensitivity (Supports)	v::NTRK3	Any solid tumor	Larotrectinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib
Sensitivity (Supports)	BCR::ABL1	Chronic Myelogenous Leukemia	Nilotinib
Sensitivity (Supports)	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel
Sensitivity (Supports)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Zanubrutinib
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Zanubrutinib
Sensitivity (Supports)	17p deletion	Chronic Lymphocytic Leukemia	Zanubrutinib
Sensitivity (Supports)	HER2-negative	Invasive Breast Carcinoma	Bevacizumab, Paclitaxel
Sensitivity (Supports)	EGFR oncogenic variants	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (Supports)	HER2-positive	Gastrointestinal Stromal Tumor	Trastuzumab
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
Sensitivity (Supports)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Fluorouracil, Tislelizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Cisplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Fluorouracil, Oxaliplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Oxaliplatin, Paclitaxel, Tislelizumab
Sensitivity (Supports)	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab
Sensitivity (Supports)	HER2-negative, PD-L1 (TAP) >= 1%	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Capecitabine, Oxaliplatin, Tislelizumab
Sensitivity (Supports)	HER2-negative, PD-L1 (CPS) >= 1	Adenocarcinoma of the Gastroesophageal Junction	Cisplatin, Fluorouracil, Tislelizumab
Sensitivity (Supports)	v::NRG1	Non-Small Cell Lung Cancer	Zenocutuzumab
Sensitivity (Supports)	v::NRG1	Pancreatic Adenocarcinoma	Zenocutuzumab
Sensitivity (Supports)	5q deletion	Myelodysplastic Syndromes	Lenalidomide
Sensitivity (Supports)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
Sensitivity (Supports)	Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
Sensitivity (Supports)	Wild type ALK	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	EGFR somatic variants	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	ER negative, HER2-negative, PD-L1 >= 1%, PR negative	Invasive Breast Carcinoma	Atezolizumab, Nab-paclitaxel
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Acalabrutinib
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Acalabrutinib
Sensitivity (Supports)	17p deletion	Chronic Lymphocytic Leukemia	Acalabrutinib
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	HER2-low	Invasive Breast Carcinoma	Trastuzumab deruxtecan
Sensitivity (Supports)	ERBB2 oncogenic variants	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan
Sensitivity (Supports)	HER2-positive	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan
Sensitivity (Supports)	HER2-positive	Any solid tumor	Trastuzumab deruxtecan
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab deruxtecan
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Carboplatin, Paclitaxel, Pembrolizumab
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Tamoxifen
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Tamoxifen
Sensitivity (Supports)	v::ALK	Non-Small Cell Lung Cancer	Ensartinib
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Rituximab
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Diffuse Large B-Cell Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Burkitt Lymphoma	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Mature B-Cell Neoplasms	Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
Sensitivity (Supports)	CD20 +	Chronic Lymphocytic Leukemia	Cyclophosphamide, Fludarabine, Rituximab
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Midostaurin
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Margetuximab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Eribulin, Margetuximab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Gemcitabine, Margetuximab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Margetuximab, Vinorelbine
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
Sensitivity (Supports)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
Sensitivity (Supports)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (Supports)	TP53 deletion	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (Supports)	17p deletion	Chronic Lymphocytic Leukemia	Ibrutinib
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	ER positive, PR positive	Invasive Breast Carcinoma	Anastrozole
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Midostaurin
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600K	Melanoma	Binimetinib, Encorafenib
Sensitivity (Supports)	BRAF p.V600E	Non-Small Cell Lung Cancer	Binimetinib, Encorafenib
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Trastuzumab, Tucatinib
Sensitivity (Supports)	HER2-positive, Wild type KRAS, Wild type NRAS	Colorectal Adenocarcinoma	Trastuzumab, Tucatinib
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
Sensitivity (Supports)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
Sensitivity (Supports)	IDH1 p.R132C	Acute Myeloid Leukemia	Olutasidenib
Sensitivity (Supports)	IDH1 p.R132G	Acute Myeloid Leukemia	Olutasidenib
Sensitivity (Supports)	IDH1 p.R132H	Acute Myeloid Leukemia	Olutasidenib
Sensitivity (Supports)	IDH1 p.R132L	Acute Myeloid Leukemia	Olutasidenib
Sensitivity (Supports)	IDH1 p.R132S	Acute Myeloid Leukemia	Olutasidenib
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Ipilimumab, Nivolumab
Sensitivity (Supports)	FLT3-ITD	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	FLT3 p.D835Y	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	FLT3 p.D835A	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	FLT3 p.D835E	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	FLT3 p.D835H	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	FLT3 p.D835N	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	FLT3 p.D835S	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	FLT3 p.D835V	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	FLT3 p.I836del	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	CDK12 oncogenic variants	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Midostaurin
Sensitivity (Supports)	CD33 +	Acute Myeloid Leukemia	Cytarabine, Daunorubicin, Gemtuzumab ozogamicin
Sensitivity (Supports)	BRAF p.V600E	Melanoma	Vemurafenib
Sensitivity (Supports)	BRAF p.V600E	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib
Sensitivity (Supports)	BRAF p.V600K	Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease	Vemurafenib
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Nivolumab
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (Supports)	CD274 amplification, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Head and Neck Squamous Cell Carcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 (CPS) >= 1	Cervical Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	MSI-H	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	dMMR	Colorectal Adenocarcinoma	Pembrolizumab
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
Sensitivity (Supports)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
Sensitivity (Supports)	ER positive, HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (Supports)	ER positive, HER2-positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (Supports)	HER2-positive, PR positive	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
Sensitivity (Supports)	PD-L1 >= 1%	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Pemetrexed
Sensitivity (Supports)	EZH2 p.Y646N	Follicular Lymphoma	Tazemetostat
Sensitivity (Supports)	EZH2 p.Y646F	Follicular Lymphoma	Tazemetostat
Sensitivity (Supports)	EZH2 p.Y646H	Follicular Lymphoma	Tazemetostat
Sensitivity (Supports)	EZH2 p.Y646S	Follicular Lymphoma	Tazemetostat
Sensitivity (Supports)	EZH2 p.Y646C	Follicular Lymphoma	Tazemetostat
Sensitivity (Supports)	EZH2 p.A862G	Follicular Lymphoma	Tazemetostat
Sensitivity (Supports)	EZH2 p.A692V	Follicular Lymphoma	Tazemetostat
Sensitivity (Supports)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
Sensitivity (Supports)	t(KMT2A;v)	Acute Lymphoid Leukemia	Revumenib
Sensitivity (Supports)	t(KMT2A;v)	Acute Myeloid Leukemia	Revumenib
Sensitivity (Supports)	t(KMT2A;v)	Burkitt Lymphoma	Revumenib
Sensitivity (Supports)	t(KMT2A;v)	Acute Leukemias of Ambiguous Lineage	Revumenib
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Myeloid Leukemia	Revumenib
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Lymphoid Leukemia	Revumenib
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Burkitt Lymphoma	Revumenib
Sensitivity (Supports)	NPM1 p.W288Cfs*12	Acute Leukemias of Ambiguous Lineage	Revumenib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Carboplatin, Osimertinib, Pemetrexed
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Cisplatin, Osimertinib, Pemetrexed
Sensitivity (Supports)	EGFR p.T790M	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	EGFR p.L858R	Non-Small Cell Lung Cancer	Osimertinib
Sensitivity (Supports)	MET Exon 14 (Splice Site)	Non-Small Cell Lung Cancer	Tepotinib
Sensitivity (Supports)	MET Exon 14 (Deletion)	Non-Small Cell Lung Cancer	Tepotinib
Sensitivity (Supports)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Rucaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Rucaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Rucaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Rucaparib
Sensitivity (Supports)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Rucaparib
Sensitivity (Supports)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Rucaparib
Sensitivity (Supports)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Rucaparib
Sensitivity (Supports)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Rucaparib